ArticleNPJ digital medicine2025
Constructing multicancer risk cohorts using national data from medical helplines and secondary care.
Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identification of cohorts at higher risk of cancer can enable earlier diagnosis of the disease, which significantly improves patient outcomes. In this study, we select nine cancer sites with high incidence of late-stage diagnosis or worsening survival rates, and where there are currently no national screening programmes. We use data from medical helplines (NHS 111) and secondary care appointments from all hospitals in England. We show that features based on information captured in NHS 111 calls are among the most influential in driving predictions of a future cancer diagnosis. Our predictive models exhibit good discrimination, ranging from 0.69 (ovarian cancer) to 0.83 (oesophageal cancer). We present an approach of constructing cohorts at higher risk of cancer based on feature importance and considering possible bias in model results. This approach is flexible and can be tailored based on data availability and the group the intervention targets (i.e. symptomatic or asymptomatic patients).
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.